

**Subject:** Multiple Sclerosis Treatment Testimonial  
**From:** "Esperanza" <esperanzapeptide@btinternet.com>  
**Date:** Wed, 14 Jun 2006 00:31:03 +0100  
**To:** "Esperanza" <esperanzapeptide@btinternet.com>  
**X-Account-Key:** account6  
**X-UIDL:** AP2yo0IAAPf3RI9K9whY9GNh43g  
**X-Mozilla-Status:** 0001  
**X-Mozilla-Status2:** 10000000  
**X-Apparently-To:** eriksmithx@yahoo.com via 66.163.178.253; Tue, 13 Jun 2006 16:32:06 -0700  
**X-Originating-IP:** [217.12.12.202]  
**Authentication-Results:** mta105.mail.re4.yahoo.com from=btinternet.com; domainkeys=neutral (no sig)  
**Received:** from 217.12.12.202 (HELO smtp812.mail.ukl.yahoo.com) (217.12.12.202) by mta105.mail.re4.yahoo.com with SMTP; Tue, 13 Jun 2006 16:32:06 -0700  
**Received:** (qmail 50255 invoked from network); 13 Jun 2006 23:32:00 -0000  
**Received:** from unknown (HELO default5711f29) (esperanzapeptide@btinternet.com@81.151.30.123 with login) by smtp812.mail.ukl.yahoo.com with SMTP; 13 Jun 2006 23:31:18 -0000  
**Message-ID:** <022f01c68f41\$70f8fd50\$7b1e9751@default5711f29>  
**MIME-Version:** 1.0  
**Content-Type:** multipart/mixed; boundary="-----\_NextPart\_000\_021A\_01C68F49.D211BC00"  
**X-Priority:** 3  
**X-MSMail-Priority:** Normal  
**X-Mailer:** Microsoft Outlook Express 6.00.2900.2869  
**X-MimeOLE:** Produced By Microsoft MimeOLE V6.00.2900.2869

## Multiple Sclerosis Treatment Testimonial

**Please feel free to pass this on to anyone that may be interested in  
the results of this treatment!**



**I am still on the peptide (since March 2005) and it has slowed the disease down considerably. Every day is different. The peptide has given me much needed hope! When I came home from the Bahamas, I started going swimming at the "Y" twice a week which I am still doing that. A great advantage to me now, is that instead of sliding from my chair at work to my wheelchair I stand and transfer myself under my own control (which I could not do prior to going on the peptide). I also try to do standing exercises at least 3 times a day.**

**Debbie Hicken**

**Canada**



**For more details please feel free to click on any of the links below:**

Main Page: <http://www.esperanzapeptide.net>

Treatment Program: <http://www.esperanzapeptide.net/treatment-program.php>

Questions & Answers: <http://www.esperanzapeptide.net/questions-answers.php>

Travel To Our Clinic: <http://www.esperanzapeptide.net/travel.php>

News & Testimonials: <http://www.esperanzapeptide.net/news-testimonials.php>

Trial Program: <http://www.esperanzapeptide.net/trial.php>

Our Technology: <http://www.esperanzapeptide.net/technologies.php>

Executive Summary: <http://www.esperanzapeptide.net/executive-summary.php>

**NEW - PowerPoint Presentation:**

**See attached or go to:**

<http://www.esperanzapeptide.net/power-point/pharma-tech-science.ppt>

**Published in:**





Daily Protech Updates... www.genengr.com

# GENETIC ENGINEERING


GEN Celebrates Its 20th Anniversary in 2000 NEWS

## Delivery of Peptide Therapeutics

Companies Explore Inhalable, Spray and Lipid Particle Technologies

Neil McGinnis, Ph.D.

Inhalable Therapeutics is currently exploring various technologies for the delivery of peptide therapeutics. The use of inhalable and spray technologies offers a non-invasive route of administration for peptide therapeutics. The use of lipid particles offers a potential route of administration for peptide therapeutics. The use of inhalable and spray technologies offers a non-invasive route of administration for peptide therapeutics. The use of lipid particles offers a potential route of administration for peptide therapeutics.



The use of inhalable peptide therapeutics offers a non-invasive route of administration for peptide therapeutics. The use of spray technologies offers a non-invasive route of administration for peptide therapeutics. The use of lipid particles offers a potential route of administration for peptide therapeutics.

Part 1.1.3

Content-Type: text/plain  
Content-Encoding: 7bit

Part 1.1.7

Content-Type: text/plain  
Content-Encoding: 7bit

Part 1.1.9

Content-Type: text/plain  
Content-Encoding: 7bit

<b>Part 1.1.11</b>	<b>Content-Type:</b> text/plain <b>Content-Encoding:</b> 7bit
--------------------	--

---

<b>Part 1.1.13</b>	<b>Content-Type:</b> text/plain <b>Content-Encoding:</b> 7bit
--------------------	--

---

<b>Part 1.1.15</b>	<b>Content-Type:</b> text/plain <b>Content-Encoding:</b> 7bit
--------------------	--

---

<b>Part 1.1.17</b>	<b>Content-Type:</b> text/plain <b>Content-Encoding:</b> 7bit
--------------------	--

---

<b>Pharma_TechScience 5.ppt</b>	<b>Content-Type:</b> application/vnd.ms-powerpoint <b>Content-Encoding:</b> base64
---------------------------------	---